(AOF) – Clariane is organizing an information meeting today during which the group will present its strategic plan and its outlook for the period 2023-2026. Over this period, the retirement home specialist anticipates average annual organic growth in its turnover of around 5%, “supported in particular by a progressive and regular increase in its occupancy rates, and its volumes of activity, particularly ambulatory, and the ongoing price catch-up, particularly in Germany.
Clariane is also aiming for an improvement of 100 to 150 basis points in its Ebitda margin, pre-IFRS16, “supported mainly by the growth in its turnover as well as by targeted improvement measures relating to its structure of central costs, on rent expenses and on energy expenses”.
The company is targeting financial leverage of less than 3 from the end of 2025 with an LTV of 55% for real estate debt.
At the same time, the group has set 2026 objectives in terms of ESG, including more than 7,000 employees engaged in a diploma course through Clariane University and a frequency rate of workplace accidents with lost time reduced to 29.
“After approval by the combined general meeting of June 10 of the terms of execution of the capital increase provided for in our plan to strengthen our financial structure, we will be able to open a new chapter, with the support of our shareholders (… )” declared Sophie Boissard, administrator and general manager of the group.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Oncology, priority of pharmaceutical giants
Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D which weigh on profitability. Sanofi therefore announced a drop in its earnings per share in 2024 and the abandonment of its objective of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to $22 billion to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States represents nearly half of global oncology spending (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, going from 5 to 11.8 billion dollars.